SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
______________
Date of Report (Date of earliest event reported): March 12, 2002
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-26642 87-0494517
- ------------------ --------------------- --------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation) xx-xxxxxxx
320 Wakara Way
Salt Lake City, Utah 84108
__________________________________________________
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
_____________________________________________________________
(Former name or former address, if changed since last report)
Page 1 of 4 pages
Item 5. Other Events.
On March 12, 2002, the Registrant publicly disseminated a press release
announcing that the Registrant has formed a drug discovery collaboration with
Abbott Laboratories to identify novel genes and drug targets for the diagnosis
and treatment of depression. The information contained in the press release is
incorporated herein by reference and filed as Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
99.1 The Registrant's Press Release dated March 12, 2002.
Page 2 of 4 pages
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Myriad Genetics, Inc.
---------------------
(Registrant)
Date: March 12, 2002 By: /s/ Peter D. Meldrum
-----------------------
Peter D. Meldrum
President and Chief Executive Officer
Page 3 of 4 pages
EXHIBIT INDEX
-------------
Exhibit
Number Description
- ------- -----------
99.1 The Registrant's Press Release
dated March 12, 2002.
Page 4 of 4 pages